Solid Biosciences (SLDB) Capital Expenditures Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 227.76% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 0.57% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 143.40% |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | -68.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.75% |
| Dec 31, 2025 | -686.11% |
| Sep 30, 2025 | -1,187.50% |
| Jun 30, 2025 | 427.91% |
| Mar 31, 2025 | -46.31% |
| Dec 31, 2024 | -102.38% |
| Sep 30, 2024 | 111.35% |
| Jun 30, 2024 | 64.66% |
| Mar 31, 2024 | -70.55% |
| Dec 31, 2023 | 388.71% |
| Sep 30, 2023 | 63.19% |
| Jun 30, 2023 | -208.63% |
| Mar 31, 2023 | 91.67% |
| Dec 31, 2022 | 159.96% |
| Sep 30, 2022 | -166.72% |
| Jun 30, 2022 | 2,700.00% |
| Mar 31, 2022 | 654.29% |
| Dec 31, 2021 | -961.67% |
| Sep 30, 2021 | 617.50% |
| Jun 30, 2021 | -98.30% |
| Mar 31, 2021 | -36.36% |
| Dec 31, 2020 | -90.70% |
| Sep 30, 2020 | -87.69% |
| Jun 30, 2020 | -38.19% |
| Mar 31, 2020 | -97.18% |
| Dec 31, 2019 | 46.92% |
| Sep 30, 2019 | 117.55% |
| Jun 30, 2019 | -64.58% |
| Mar 31, 2019 | 95.10% |
| Dec 31, 2018 | 126.05% |
| Sep 30, 2018 | -327.10% |
| Jun 30, 2018 | 961.39% |
| Mar 31, 2018 | 6,156.25% |